

Figure S1. Distribution of treatment-naïve patients by year (2014-2020) and STR/MTR (a), NRTI backbones (b), ART regimens (c).

Abbreviation: 3TC, lamivudine; ABC, abacavir; DTG, dolutegravir; ART, combination antiretroviral treatment; FTC, emtricitabine; INSTI, integrase strand transfer inhibitor; MTR, Multiple Tablet Regimen; NRTI, nucleos(t)ide reverse transcriptase inhibitors; NNRTI, non-nucleoside reverse transcriptase inhibitors; PI, protease inhibitor; STR, Single Tablet Regimen; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.




Figure S2. Distribution of treatment-experienced patients by year (2014-2020) and STR/MTR (a), NRTI backbones (b), ART regimens (c).

Abbreviation: 3TC, lamivudine; ABC, abacavir; DTG, dolutegravir; ART, combination antiretroviral treatment; FTC, emtricitabine; INSTI, integrase strand transfer inhibitor; MTR, Multiple Tablet Regimen; NRTI, nucleos(t)ide reverse transcriptase inhibitors; NNRTI, non-nucleoside reverse transcriptase inhibitors; PI, protease inhibitor; STR, Single Tablet Regimen; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.